Novel Foods: EU platform streamlines approvals; NZ reforms; FDA targets GRAS oversight
New regulatory initiatives in the EU, New Zealand, and the US are poised to reshape market access and compliance for novel ingredients and natural health products. Companies must prepare for accelerated approval pathways, revised health claim frameworks, and intensified safety substantiation demands.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Brussels, Belgium — 19 October 2026
The European Union has launched New Foods RegLab, a new platform designed to accelerate novel food approvals. This initiative aims to streamline market access for innovative ingredients, such as algae bioactives and alternative proteins, by improving regulatory guidance and facilitating knowledge sharing. Companies operating within the EU can anticipate a more efficient approval process, potentially reducing lead times for novel ingredient incorporation into new products, as reported by NutraIngredients Global.
Concurrently, New Zealand is consulting on significant reforms to its natural health product regulations. The proposed changes focus on health claims and aim to enhance both consumer confidence and industry innovation. Manufacturers and brand owners targeting the New Zealand market must closely monitor these consultations to adapt product positioning and claim substantiation strategies. Successful navigation of these reforms could unlock new growth opportunities in a market prioritising evidence-based natural health products.
Across the Atlantic, the US Food and Drug Administration (FDA) is proposing a critical shift from voluntary to mandatory Generally Recognised As Safe (GRAS) notifications for food additives. This move intends to enhance oversight and transparency, particularly favouring suppliers capable of providing strong scientific evidence for their ingredients' safety. The transition will demand more rigorous data packages and potentially extended pre-market preparation for new ingredients, impacting US market entry strategies.
What this means for United Kingdom
UK manufacturers and brand owners operating within or importing to the EU will directly benefit from the New Foods RegLab’s acceleration of novel food approvals, potentially shortening their ingredient sourcing and product development cycles for EU-compliant formulations. For those with US market aspirations, the FDA’s mandatory GRAS notifications necessitate a proactive review of existing ingredient safety dossiers and an increased investment in scientific substantiation, with a compliance deadline likely in mid-2026. Conversely, brand owners supplying to New Zealand must prepare for potential changes in permitted health claims, necessitating reformulation or relabelling by late 2025 to maintain market access and competitiveness. This also offers an opportunity for UK companies to export well-substantiated products into a more regulated NZ market.
Commercial Implications
- Manufacturers must assess their novel ingredient pipelines for EU market readiness and leverage the new RegLab for expedited approvals.
- Suppliers must audit their GRAS documentation to meet upcoming mandatory FDA requirements, or risk market access disruption in the US.
- Brand owners should engage with New Zealand's consultation process to influence future natural health product regulations and prepare for revised health claims frameworks.
Many leading brands in this category are manufactured in partnership with Supplement Factory.